Business
Tarsus to Buy Alkeus for Up to $800M, Betting on a Drug for a Rare Blinding Disease
The deal adds gildeuretinol, a modified vitamin A in Phase 3 for Stargardt disease, to Tarsus — a program championed by Vertex founder Josh Boger.